Clinical Trial Search

Primary: Number of Participants With Anti-recombinant Thrombin (rThrombin) Product Antibodies at Day 29 in Participants With and Without Anti-bovine Thrombin Product Antibodies…

Primary: Number of Participants With Adverse Events (AE) — 501; 170 participants

Primary: Trabecular Bone Volume to Tissue Volume at Distal Radius, Percent Change From Baseline to Month 12 — -1.486; -1.255 Percent Change — p=0.7096

Primary: Pain VAS (Visual Analog Scale) Response. Percentage of Subjects With a Greater Than or Equal to 30% Reduction in Pain VAS From Baseline (BOCF). — 20.2; 35.4; 35.3; 79.8…

Primary: Summary and Analysis of Sum of Pain Intensity Difference (SPID) (With Imputation) Over 3 Days (72 Hours) — 34.8; 40.5 Scores on a scale — p=0.5265

Primary: Resolution of Anterior Chamber Cells (ACC). — 62; 33 Eyes — p=<0.001

Primary: Change From Baseline in Hemoglobin Concentration to the Last Month of Study Participation — -0.55; -0.38 g/dL

Primary: Change From Double-blind Baseline (Week 26) in Sitting Clinic Diastolic Blood Pressure to Week 32 — 0.14; 7.92 mmHg — p=<0.001

Primary: Clinical and Mycological Cure of Target Toenail — 22.3; 1 Percentage of participants — p=<0.001

Primary: Correction of Astigmatism — -0.54; -0.59 diopter — p=<0.05

Primary: Change in the International Cooperative Ataxia Rating Scale (ICARS) From Baseline Assessment to Week 24 — -2.5; -2.4; -1.3 ICARS points

Primary: Maximum Observed Plasma Concentration (Cmax) — 136; 798; 1643; 2067 nanogram per milliliter (ng/mL)

Primary: Time to First New Flare: Survival Analysis During the 12 Weeks of Study — NA; NA Days

Primary: Change From Baseline in Total International Prostate Symptom Score (IPSS) at 12 Weeks — -4.2; -6.3; -5.7 units on a scale — p=0.001

Primary: Change From Baseline in Left Ventricular Mass Index (LVMI) Over 48 Weeks Measured by Cardiac Magnetic Resonance Imaging (MRI) — 0.34; -0.07 grams/meter^2.7 — p=0.145